Evaluation of expression based markers for the detection of breast cancer cells

  • Nicholas M. Brown
  • Timothy T. Stenzel
  • Paula N. Friedman
  • Jerry Henslee
  • Gudrun Huper
  • Jeffrey R. Marks
Original paper

Summary

Introduction

Genes that are expressed in a highly tissue- or disease-specific manner provide possible targets for therapeutics, early detection of cancer, and monitoring of disease burden during and after treatment. Further, genes of this type that code for secreted or shed proteins may allow for serum detection of the product facilitating our ability to specifically detect the cancer in all circumstances. To this end, we are working towards identification and characterization of such genes that are specifically expressed in breast epithelium. In the current study, we have measured the expression of two markers that emerged from a screen of the Incyte LifeSeq Database and were subsequently shown to be highly restricted to breast epithelium termed BU101 (also called Lipophilin B) and BS106 (small mucin-like protein). These two novel markers were compared with two other candidate markers, Mammaglobin and Cytokeratin 19 (CK19).

Methods

Utilizing quantitative real-time PCR, we compared the expression of these four genes in a series of 95 primary breast cancers, 9 lymph nodes from breast cancer patients, 13 lymph nodes from non-cancer patients and 10 normal breast tissues.

Results

Cytokeratin was shown to be highly sensitive in detecting all breast cancers, while BU101, BS106 and Mammaglobin were more restricted.

Conclusion

While no one of the these markers efficiently detects all breast cancers, a combination of two or more could achieve a very high sensitivity in assaying for circulating or occult breast cancer cells.

Keywords

BS106 Cytokeratin 19 gene expression Lipophilin B Mammaglobin RT-PCR 

References

  1. 1.
    Schulze R, Schulze M, Wischnik A, Ehnle S, Doukas K, Behr W, Ehret W, Schlimok G, 1997 Tumor cell contamination of peripheral blood stem cell transplants and bone marrow in high-risk breast cancer patients Bone Marrow Transpl 19: 1223–1228CrossRefGoogle Scholar
  2. 2.
    Vannucchi AM, Bosi A, Glinz S, Pacini P, Linari S, Saccardi R, Alterini R, Rigacci L, Guidi S, Lombardini L, Longo G, Mariani MP, Rossi-Ferrini P, 1998: Evaluation of breast tumour cell contamination in the bone marrow and leukapheresis collections by RT-PCR for cytokeratin-19 mRNA Brit J Haematol 103: 610–617CrossRefGoogle Scholar
  3. 3.
    Shammas FV, Deak E, Nysted A, van Eekelen JA, Osland A, Heikkila R, 2001 Serial quantitative PCR analysis of bone marrow samples from breast cancer patients to monitor systemic micrometastases Anticancer Res 21: 2099–2106PubMedGoogle Scholar
  4. 4.
    Ikeda N, Miyoshi Y, Motomura K, Inaji H, Koyama H, Noguchi S, 2000 Prognostic significance of occult bone marrow micrometastases of breast cancer detected by quantitative polymerase chain reaction for cytokeratin 19 mRNA Jpn J Cancer Res 91: 918–924PubMedGoogle Scholar
  5. 5.
    Kahn HJ, Yang LY, Lickley L, Holloway C, Hanna W, Narod S, McCready DR, Seth A, Marks A, 2000 RT-PCR amplification of CK19 mRNA in the blood of breast cancer patients: correlation with established prognostic parameters Breast Cancer Res Treat 60: 143–151CrossRefPubMedGoogle Scholar
  6. 6.
    Colpitts TL, Billing-Medel P, Friedman P, Granados EN, Hayden M, Hodges S, Menhart N, Roberts L, Russell J, Stroupe SD, 2001 Mammaglobin is found in breast tissue as a complex with BU101 Biochem 40: 11048–11059CrossRefGoogle Scholar
  7. 7.
    Zhao C, Nguyen T, Yusifov T, Glasgow BJ, Lehrer RI, 1999 Lipophilins: human peptides homologous to rat prostatein Biochem Biophys Res Commun 256: 147–155CrossRefPubMedGoogle Scholar
  8. 8.
    Mukherjee AB, Kundu GC, Mantile-Selvaggi G, Yuan CJ, Mandal AK, Chattopadhyay S, Zheng F, Pattabiraman N, Zhang Z, 1999 Uteroglobin: a novel cytokine? Cell Mol Life Sci 55: 771–787CrossRefPubMedGoogle Scholar
  9. 9.
    Mukherjee AB, Kundu GC, Mandal AK, Pattabiraman N, Yuan CJ, Zhang Z, 1998 Uteroglobin: physiological role in normal glomerular function uncovered by targeted disruption of the uteroglobin gene in mice Am J Kidney Dis 32: 1106–1120CrossRefPubMedGoogle Scholar
  10. 10.
    Miele L, 2000 Antiflammins. Bioactive peptides derived from uteroglobin Ann N Y Acad Sci 923: 128–140PubMedGoogle Scholar
  11. 11.
    Miele L, Cordella-Miele E, Mukherjee AB, 1987 Uteroglobin: structure, molecular biology, and new perspectives on its function as a phospholipase A2 inhibitor Endocr Rev 8: 474–490PubMedCrossRefGoogle Scholar
  12. 12.
    Vasanthakumar G, Manjunath R, Mukherjee AB, Warabi H, Schiffmann E, 1988 Inhibition of phagocyte chemotaxis by uteroglobin, an inhibitor of blastocyst rejection Biochem Pharmacol 37: 389–394CrossRefPubMedGoogle Scholar
  13. 13.
    Levin SW, Butler JD, Schumacher UK, Wightman PD, Mukherjee AB, 1986 Uteroglobin inhibits phospholipase A2 activity Life Sci 38: 1813–1819CrossRefPubMedGoogle Scholar
  14. 14.
    Watson MA, Fleming TP, 1996 Mammaglobin, a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer Cancer Res 56: 860–865PubMedGoogle Scholar
  15. 15.
    Colpitts TL, Billing P, Granados E, Hayden M, Hodges S, Roberts L, Russell J, Friedman P, Stroupe S, 2002 Identification and immunohistochemical characterization of a mucin-like glycoprotein expressed in early stage breast carcinoma Tumor Biol 23: 263–278CrossRefGoogle Scholar
  16. 16.
    Miksicek RJ, Myal Y, Watson PH, Walker C, Murphy LC, Leygue E, 2002 Identification of a novel breast- and salivary gland-specific, mucin- like gene strongly expressed in normal and tumor human mammary epithelium Cancer Res 62: 2736–2740PubMedGoogle Scholar
  17. 17.
    Iglehart JD, Kerns BJ, Huper G, Marks JR, 1995 Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer Breast Cancer Res Treat 34: 253–263CrossRefPubMedGoogle Scholar
  18. 18.
    Davidoff AM, Humphrey PA, Iglehart JD, Marks JR, 1991 Genetic basis for p53 overexpression in human breast cancer Proc Natl Acad Sci U S A 88: 5006–5010CrossRefPubMedGoogle Scholar
  19. 19.
    Davidoff AM, Kerns BJ, Iglehart JD, Marks JR, 1991 Maintenance of p53 alterations throughout stages of breast cancer progression Cancer Res 51: 2605–2610PubMedGoogle Scholar
  20. 20.
    Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmuller G, Schlimok G, 2000 Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer N Engl J Med 342: 525–533CrossRefPubMedGoogle Scholar
  21. 21.
    Schreiber RH, Pendas S, Ku NN, Reintgen DS, Shons AR, Berman C, Boulware D, Cox CE, 1999 Microstaging of breast cancer patients using cytokeratin staining of the sentinel lymph node. [see comments] Ann Surg Oncol 6: 95–101CrossRefPubMedGoogle Scholar
  22. 22.
    Colpaert C, Vermeulen P, Jeuris W, van Beest P, Goovaerts G, Weyler J, Van Dam P, Dirix L, Van Marck E, 2001 Early distant relapse in “node-negative” breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour J Pathol 193: 442–449CrossRefPubMedGoogle Scholar
  23. 23.
    Lambrechts AC, Bosma AJ, Klaver SG, Top B, Perebolte L, van’t Veer LJ, Rodenhuis S, 1999 Comparison of immunocytochemistry, RT-PCR, and nucleic acid sequence-based amplification for the detection of circulating breast cancer cells Breast Cancer Res Treat 56: 219–231CrossRefPubMedGoogle Scholar
  24. 24.
    Grunewald K, Haun M, Urbanek M, Fiegl M, Muller-Holzner E, Gunsilius E, Dunser M, Marth C, Gastl G, 2000 Mammaglobin gene expression: a superior marker of breast cancer cells in peripheral blood in comparison to epidermal-growth- factor receptor and cytokeratin-19 Lab Invest 80: 1071–1077PubMedGoogle Scholar
  25. 25.
    Aerts J, Wynendaele W, Paridaens R, Christiaens MR, van den Bogaert W, van Oosterom AT, Vandekerckhove F, 2001 A real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to detect breast carcinoma cells in peripheral blood Ann Oncol 12: 39–46CrossRefPubMedGoogle Scholar
  26. 26.
    Slade MJ, Smith BM, Sinnett HD, Cross NC, Coombes RC, 1999 Quantitative polymerase chain reaction for the detection of micrometastases in patients with breast cancer J Clin Oncol 17: 870–879PubMedGoogle Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • Nicholas M. Brown
    • 1
    • 4
  • Timothy T. Stenzel
    • 1
    • 5
  • Paula N. Friedman
    • 2
  • Jerry Henslee
    • 2
  • Gudrun Huper
    • 3
  • Jeffrey R. Marks
    • 1
    • 3
  1. 1.Department of PathologyDuke University Medical CenterDurhamUSA
  2. 2.Abbott Laboratories Diagnostic DivisionAbbott ParkUSA
  3. 3.Department of SurgeryDuke University Medical CenterDurhamUSA
  4. 4.Quest DiagnosticsChantillyUSA
  5. 5.Vysis, Inc.Downers GroveUSA
  6. 6.Department of SurgeryDuke University Medical CenterDurhamUSA

Personalised recommendations